myriad. | Hereditary Cancer Test Request Form

page **1** of 2

Make sure information is complete and legible

Please submit both pages of this form

FOR LAB USE

s	PECIMEN COLLECTION DATE (REQUIRED
· · · · · · · · · · · · · · · · · · ·	
I	

NOTE: Affix Patient Identifier Label to Specimen Tube

1. Patient Information (Complete information required)

Name (last, first, middle initial)	Gende	er 🗌 Male 🗌 Female	Birthdate (MM,	/DD/YYYY)	Patient ID #	Email
Address	City	State	Zip	Cell phone		Daytime phone

2. Ordering Physician Information (Only name and HCP Account # required unless you're a new customer or HCP # is unknown)

Name (last, first)		Myriad HCP Account #	Degree	NPI #
Address		City	State	Zip
Office Contact Name	Phone	Fax	Email	

3. Additional Results Recipient (Additional clinician will receive cancellation notices and patient's copy of the test results)

Name (last, first)		Myriad HCP Account #	Degree	NPI #
Address		City	State	Zip
Office Contact Name	Phone	Fax	Email	

4. Test Requested (For test descriptions see reverse)	Tests ordered will be processed and billed based on payer criteria.
□ Integrated BRACAnalysis [®] with Myriad myRisk [®] Hereditary Cancer Update Test (HBOC criteria)	Specify Gene: and Mutation: Specify Gene: and Mutation:
 Multisite 3 BRACAnalysis REFLEX to Integrated BRACAnalysis with Myriad myRisk Hereditary Cancer Update Test if the Multisite 3 is negative 	Relationship: My patient is the (e.g., maternal aunt) of the known mutation carrier. Required: Include a copy of the known mutation carrier's report.
 Check here if a family member has tested positive for one of the Multisite 3 mutations (see reverse) 	Myriad myRisk <u>Update</u> Test (available to patients previously tested negative with BRACAnalysis [®] , COLARIS [®] , and/or COLARIS AP [®] . BART and/or
COLARIS ^{®PLUS} with Myriad myRisk Hereditary Cancer Update Test (Lynch criteria)	<i>PMS2</i> testing will be included in the test order unless previously performed or restricted by payor criteria.)
COLARIS AP ^{®PLUS} with Myriad myRisk Hereditary Cancer Update Test (Familial Polyposis syndrome criteria)	Other (e.g. single gene analysis):

5. Confirmation of Informed Consent & Statement of Medical Necessity

I affirm each of the following: I have provided genetic testing information to the patient and the patient has consented to genetic testing. This test is medically necessary for the diagnosis of a disease or syndrome. The results will be used in the patient's medical management and treatment decisions. The person listed as the Ordering Physician is authorized by law to order the test(s) requested herein.

	SIGN HERE: Medical Professional (required to process form)	X	Date: _			
		/		(Signature date is the specimen collection		
				date if a different date is not provided above)		

6. Billing/Payment Information

OPTION 1: BILL INSURANCE (Please attach copy of authorization/referral)						
Name of Policy Holder:	DOB: Insurance ID#:					
Patient Relation to Policy Holder: \Box Self \Box Spouse \Box Child	□ Other Authorization/Referral	card(s).				
SIGN HERE: Patient/Responsible Party I AGREE TO THE BILLING TERMS ON REVERSE X	DATE:	If you submit more than one card, indicate which is primary.				
I understand that Myriad will contact me if I will be financially responsible for any non-covered service. To be considered for the Myriad Financial Assistance Program, please provide the following information: Annual household income \$ Number of family members in household						
OPTION 2: PATIENT PAYMENT (Please call Customer Service for questions regarding test prices or for credit card payment)						
OPTION 3: OTHER BILLING (To establish an account, submit billing information with this form)						
Bill our institutional account #: or established rese	earch project code #:	or Authorization/Voucher #:				

MYRIAD GENETIC LABORATORIES, INC. A CLIA Certified Laboratory

320 Wakara Way • Salt Lake City, UT 84108 / (800) 469-7423 • Fax (801) 584-3615 • myriad.com

IMPORTANT INFORMATION FOR PATIENT

BILLING TERMS: I represent that I am covered by insurance and authorize Myriad Genetic Laboratories, Inc. (MGL) to give my designated insurance carrier, health plan, or third party administrator (collectively "Plan") the relavant health information necessary for reimbursement. I authorize Plan benefits to be payable to MGL. I understand MGL will contact me if I will be financially responsible for any non-covered service. I agree to assist MGL in resolving insurance claim issues and if I don't assist, I may be responsible for the full test cost. I permit a copy of this authorization to be used in place of the original.

NON-DISCRIMINATION: Federal law (GINA) and laws in most states prohibit discrimination regarding employment eligibility, health benefits, or health insurance premiums based solely on genetic information.

AFFORDABILITY: Myriad Promise™

- The majority of appropriate patients pay \$0
- Myriad will work with your insurance provider to help you get the appropriate coverage
- If you encounter ANY financial hardship associated with your bill, Myriad will work with you toward your complete satisfaction
- For more information please refer to the billing information at MyriadPromise.com

TEST DESCRIPTIONS

Integrated BRACAnalysis® with Myriad myRisk® Hereditary Cancer Update Test	Analysis of <i>BRCA1</i> and <i>BRCA2</i> for susceptibility to Hereditary Breast and Ovarian Cancer syndrome with additional genes associated with hereditary cancer risk (see table below)
Multisite 3 BRACAnalysis®	Three-mutation <i>BRCA1</i> and <i>BRCA2</i> analysis for individuals of Ashkenazi Jewish ancestry: c.5946del (p.Ser1982Argfs*22) (aka 6174delT), c.68_69del (p.Glu23Valfs*17) (aka 185delAG, 187delAG), c.5266dupC (p.Gln1756Profs*74) (aka 5385insC, 5382insC)
COLARIS ^{®PLUS} with Myriad myRisk [®] Hereditary Cancer Update Test	Analysis of <i>MLH1, MSH2, MSH6, PMS2, MUTYH,</i> and <i>EPCAM</i> for susceptibility to Lynch syndrome, with additional genes associated with hereditary cancer risk (see table below)
COLARIS AP ^{®PLUS} with Myriad myRisk [®] Hereditary Cancer Update Test	Analysis of <i>APC</i> for susceptibility to FAP/AFAP with additional genes associated with hereditary cancer risk
Single Site Testing	Analysis of single, familial mutation
Myriad myRisk® Update Test	Analysis of 28 hereditary cancer genes for patients who previously tested negative for BRAC <i>Analysis</i> [®] , COLARIS [®] , and/or COLARIS <i>AP</i> [®] . BART and/or <i>PMS2</i> testing will be included in the test order unless previously performed or restricted by payor criteria.

Genes & Associated Cancers	Br	Ov	Co	En	Me	Pa	Ga	Pr
BRCA1	•	•				•		•
BRCA2	•	•			•	•		٠
MLH1, MSH2, MSH6, PMS2, EPCAM**		•	•	•		•	•	
APC			•			٠	•	
МИТҮН			•					
CDK4, CDKN2A (p16INK4a, p14ARF)					•	•		
TP53	•	•	•	•	•	•	•	•
PTEN	•		٠	٠	٠			
STK11	•	•	•	•		•	•	
CDH1	•		•				٠	
BMPR1A, SMAD4			•			٠	•	
PALB2, ATM	•					٠		
CHEK2	•		•					•
NBN	•							•
BARD1	•							
BRIP1		•						
RAD51C, RAD51D		•						
POLD1, POLE			٠					
GREM1			•					
Br: Breast / Ov: Ovarian / Co: Colorectal / En: Endometrial / Me: Meland	oma / Pa :	Panc	reatic	/ Ga	Gast	ric / F	r: Pro	stat

Turnaround Time:

- The majority of Myriad myRisk results are completed within 14 days
- We will notify you in the unusual event results take longer than 21 days

Myriad myRisk® Report includes:

- myRisk Genetic Result
- myRisk Management Tool
 - Guideline based (NCCN, CAPS, Amsterdam, and others) cancer management for both positive and negative results

Completing the Test Request Form:

- Please include:
 - Age and cancer diagnosis
 - Gender and relationship

The myRisk Management Tool may not be reported without an accurate and specific personal and family history included on the Patient Cancer Family History Form

Br. Breast / Ov: Ovarian / Co: Colorectal / En: Endometrial / Me: Melanoma / Pa: Pancreatic / Ga: Gastric / Pr: Prostate *Additional risks may be associated with each gene/syndrome. **Large rearrangement only.

The genes associated with Myriad myRisk Hereditary Cancer[®] Panel are subject to change. To ensure you have a current version of the TRF and the genes included with the Myriad myRisk panel please visit www.myriadpro.com/documents-and-forms/test-request-forms and www.myriadpro.com/myrisk/why-myriad-myrisk/gene-selection.
 For additional information visit MySupport360.com and MyriadPro.com

Hereditary Cancer Test Request Form

7. Patient Information (Make sure information is the same as entered on page 1)

Name (last, first, middle initial)

Birthdate (MM/DD/YYYY)

8. Ancestry

Other Cancer

myriad

Select	all	that	apply:

□ White / Non-Hispanic Hispanic / Latino Black / African

🗆 Ashkenazi Jewish 🗌 Asian □ Native American

 Pacific Islander □ Middle Eastern □ Other

9. Patient Personal History of Cancer & Other Clinical Information (Select all that apply)

□ No personal history of cancer			
Patient has been diagnosed with: Age a Diagno		Patient is Currently Being Treated	Pathology / Other Info
□ Breast Cancer □ Left □ Right			□ Ductal Invasive □ Lobular Invasive □ DCIS □ Bilateral □ Premenopausal □ Triple Negative (ER-, PR-, HER2-)
Endometrial / Uterine Cancer			Tumor MSI-High or IHC Abnormal - Result
🗆 Ovarian Cancer			□ Non-epithelial
Prostate Cancer			Gleason Score
Colon / Rectal Cancer			Type: Mucinous Signet Ring Medullary Growth Pattern Tumor Infiltrating Lymphocytes Crohn's-like Lymphocytic Reaction Patient's tumor is MSI-High or IHC Abnormal - Result
🗆 Colon / Rectal Adenomas			Cumulative Adenomatous Polyp #: 1 2-5 6-9 10-19 20-99 100+
Hematologic Cancer			

Other Cancer			Туре
		_% on one of t	he Lynch Syndrome Risk Models (PREMM _{1,2,6,} MMRpro, or MMRpredict)
Check if applicable to patient:	Bone	Marrow Trans	plant Recipient

Туре

10. Family History of Cancer

Provide complete and specific information to ensure proper insurance reimbursement, determine cancer risk estimates, and optimize medical management recommendations

□ No Known Family History of Cancer

Limited Family Structure Limited family history available such as fewer than two female 1st or 2nd degree maternal or paternal relatives having lived beyond age 45

				Terrate ist er zha degree material er paterial feldates harrig itted bejond age te	
Relationship to Patient	Maternal (mother's side)	Paternal (father's side)	Cancer Site	or Polyp Type (add # for colon/rectal adenomas	(5) Age at Each Diagnosis

11. Breast Cancer Risk Model Information

• Only complete for female patients <u>NEVER</u> affected with breast cancer

PATIENT INFORMATION:	INFORMATION ABOUT PATIENT'S FEMALE RELATIVES:		
Height (ft/in):	Weight (lbs):		
Age at time of first menstrual period:	Number of daughters:		
Is patient:			
Has this patient had a live birth?: 🗆 No 🔅 Yes: ag	Number of sisters:		
Has patient ever used Hormone Replacement Thera	Number of maternal aunts (mother's sisters):		
If Yes, Treatment Type: Combined Estrogen o			
If Yes, is patient a: 🗌 Current User: Started			
Past User: Stopped			
If patient has had breast biopsy did it show:	Number of paternal aunts (father's sisters):		
🗌 No Benign Disease 🛛 Hyperplasia 🗌 Atypical Hy	perplasia 🛛 LCIS 🔲 Biopsy Result Unknown 🗌 N/A		

Myriad, the Myriad logo, Myriad myRisk Hereditary Cancer, BRACAnalysis, COLARIS and COLARIS AP are either trademarks or registered trademarks of Myriad Genetics, Inc., in the United States and other jurisdictions. ©2017 MGMRHCTCTRF / 4-17